Drugs / Latozinemab
Latozinemab
Trials 10 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 12 trials | ||||||
| Phase 1 | NCT06921590 | May → Dec 2025 overdue | — | Alzamend Neuro, Inc. | Active not recruiting | No outcome recorded |
| Phase 1 | NCT03636204 | Sep 2018 → Dec 2019 | frontotemporal dementia | Alector Inc. | Completed | No outcome recorded |
| Phase 1/23 trials | ||||||
| Phase 1/2 | NCT07540338 | Apr → Dec 2026 expected | bipolar I disorder | Alzamend Neuro, Inc. | Recruiting | No outcome recorded |
| Phase 1/2 | NCT06707753 | Sep 2023 → Aug 2025 overdue | wet macular degeneration | Beijing Anlong Biopharmaceutical Co., Ltd. | Active not recruiting | No outcome recorded |
| Phase 1/2 | NCT05363293 | May 2022 → Apr 2023 | Alzheimer disease | Alzamend Neuro, Inc. | Completed | No outcome recorded |
| Phase 23 trials | ||||||
| Phase 2 | NCT06839339 | Feb 2025 → Sep 2026 expected | wet macular degeneration | Beijing Anlong Biopharmaceutical Co., Ltd. | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT05053035 | Sep 2021 → Oct 2022 | amyotrophic lateral sclerosis | Alector Inc. | Terminated | No outcome recorded |
| Phase 2 | NCT03987295 | Sep 2019 → Jun 2024 | frontotemporal dementia | Alector Inc. | Completed | No outcome recorded |
| Phase 32 trials | ||||||
| Phase 3 | NCT06111014 | Dec 2023 → Sep 2025 | neurodegenerative disease | Alector Inc. | Terminated | No outcome recorded |
| Phase 3 | NCT04374136 | Jul 2020 → Sep 2025 | frontotemporal dementia | Alector Inc. | Terminated | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 11 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Latozinemab | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06111014 ↗ |
| Known as | AL001 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05053035 ↗ |
| Known as | Alzamend AL001 | “Alzamend AL001” NCT05363293 ↗ |
| Modality | Monoclonal antibody | — CHEMBL4650439 ↗ |
| Route | Intravenous | “intravenously administered AL001” NCT03636204 ↗ |